Every 10-Q that EyePoint (EYPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EYPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EYPT filings page.
EyePoint Pharmaceuticals (EYPT) reported a wider Q3 loss as it advances late‑stage trials. Total revenue was $0.97 million, down 91% year over year, mainly due to prior deferral recognition tied to YUTIQ® licensing. Research and development rose to $47.8 million (up 62%) as Phase 3 wet AMD studies (LUGANO, LUCIA) continued. Net loss was $59.7 million, or $0.85 per share.
Cash, cash equivalents and marketable securities were $204.0 million as of September 30, 2025. After quarter‑end, the company closed an underwritten equity offering with net proceeds of approximately $162.1 million and sold additional shares via its ATM. Management states these resources are expected to fund operations into the fourth quarter of 2027, beyond anticipated 2026 topline data for DURAVYU™.
Deferred revenue from the ANI YUTIQ® arrangement was fully recognized by Q2 2025, reducing current‑period license revenue. The company recorded a $4.7 million accrual for a potential DOJ matter resolution. Shares outstanding were 82,787,220 as of October 30, 2025.